FindTrial
Sign In

Clinical study of Huanglian Jiedu Decoction in improving the efficacy of septic cardiomyopathy patients

Clinical study of Huanglian Jiedu Decoction in improving the efficacy of septic cardiomyopathy patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000004108
Enrollment
Unknown
Registered
2020-09-23
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

septic cardiomyopathy

Interventions

experimental group:Huanglianjiedu Decoction
control group:Conventional treatment

Sponsors

Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for sepsis; 2. Aged between 18 and 70 years; 3. Meet the diagnostic criteria of sepsis cardiomyopathy; 4. Those who meet the standard of TCM syndrome differentiation and classification of heat poison; 5. Volunteer for the test.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Mental disorder or unwillingness to cooperate; 3. Patients with primary heart disease; 4. Patients with severe primary diseases and malignant tumors of liver and kidney, blood, endocrine system, etc.

Design outcomes

Primary

MeasureTime frame
HMGB1;Mitochondrial DNA;Supar;—

Countries

China

Contacts

Public ContactWei Zhou

Renji Hospital, Shanghai Jiaotong University School of Medicine

zwsyn@126.com+86 13918711438

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026